Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
Molsidomine (N-carboxy-3-morpholino-sydnonimine-ethylester; Cassella-Riedel Pharma GmbH, Frankfurt/M. FRG) has an antianginal effect for up to 3-5 h after oral administration of 2 mg Corvaton [1]. Plasma levels of the parent drug can be measured during this interval. A new galenic formulation (Corvaton retard) has been developed to prolong the duration of the therapeutic action and to improve patient compliance. The present study was carried out to establish whether the in vitro dissolution profile of the tablet was reflected in vivo, thus permitting prediction of plasma molsidomine levels in patients with coronary heart disease.
D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy / Q000378:metabolism; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy / Q000378:metabolism*; D004311:Double-Blind Method; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D008981:Molsidomine; D010069:Oxadiazoles / Q000378:metabolism*; D013558:Sydnones / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D013997:Time Factors
D010069:Oxadiazoles; D013558:Sydnones; D008981:Molsidomine